Back to Search Start Over

Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study

Authors :
Fleur van der Sijde
Marjolein Y. V. Homs
Marlies L. van Bekkum
Thierry P. P. van den Bosch
Koop Bosscha
Marc G. Besselink
Bert A. Bonsing
Jan Willem B. de Groot
Thomas M. Karsten
Bas Groot Koerkamp
Brigitte C. M. Haberkorn
Saskia A. C. Luelmo
Leonie J. M. Mekenkamp
Dana A. M. Mustafa
Johanna W. Wilmink
Casper H. J. van Eijck
Eveline E. Vietsch
on behalf of the Dutch Pancreatic Cancer Group
Source :
International Journal of Molecular Sciences, Vol 22, Iss 20, p 10902 (2021)
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC). A total of 132 PDAC patients of all disease stages were included in this study, of whom 25% showed progressive disease during FOLFIRINOX according to the RECIST criteria. MiRNA expression was analyzed in serum collected before the start and after one cycle of chemotherapy. In the discovery cohort (n = 12), a 352-miRNA RT-qPCR panel was used. In the validation cohorts (total n = 120), miRNA expression was detected using individual RT-qPCR miRNA primers. Before the start of FOLFIRINOX, serum miR-373-3p expression was higher in patients with progressive disease compared to patients with disease control after FOLFIRINOX (Log2 fold difference (FD) 0.88, p = 0.006). MiR-194-5p expression after one cycle of FOLFIRINOX was lower in patients with progressive disease (Log2 FD −0.29, p = 0.044). Both miRNAs were predictors of early tumor progression in a multivariable model including disease stage and baseline CA19-9 level (miR-373-3p odds ratio (OR) 3.99, 95% CI 1.10–14.49; miR-194-5p OR 0.91, 95% CI 0.83–0.99). MiR-373-3p and miR-194-5p did not show an association with OS after adjustment for disease stage, baseline CA19-9, and chemotherapy response. In conclusion, high serum miR-373-3p before the start and low serum miR-194-5p after one cycle are associated with early tumor progression during FOLFIRINOX.

Details

Language :
English
ISSN :
14220067 and 16616596
Volume :
22
Issue :
20
Database :
Directory of Open Access Journals
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
edsdoj.7f7eb76eff430cb27d55f8e5ca125a
Document Type :
article
Full Text :
https://doi.org/10.3390/ijms222010902